^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

TAK-007

i
Other names: TAK-007, TAK007, TAK 007, Anti-CD19 CAR NK-cell therapy, iC9/CAR.19/IL15-Transduced CB-NK Cells
Associations
Trials
Company:
Takeda, UT MD Anderson Cancer Center
Drug class:
CD19 inhibitor
Associations
Trials
6ms
A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) (clinicaltrials.gov)
P2, N=27, Active, not recruiting, Takeda | N=265 --> 27 | Recruiting --> Active, not recruiting
Enrollment closed • Enrollment change
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
BCL6 rearrangement • BCL2 rearrangement
|
cyclophosphamide • TAK-007
7ms
New P1 trial
|
cyclophosphamide • TAK-007
9ms
A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) (clinicaltrials.gov)
P2, N=265, Recruiting, Takeda | Trial completion date: Oct 2029 --> Jun 2030 | Trial primary completion date: Oct 2029 --> Oct 2025
Trial completion date • Trial primary completion date
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
BCL6 rearrangement • BCL2 rearrangement
|
cyclophosphamide • TAK-007
almost3years
Enrollment open • Clinical
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta)
|
BCL6 rearrangement • BCL2 rearrangement
|
cyclophosphamide • TAK-007
3years
Clinical • New P2 trial
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta)
|
BCL6 rearrangement • BCL2 rearrangement
|
TAK-007